Patients report menstrual changes, chills, hot flashes and fatigue that clinical trials may have missed. Separately, Stanford's AI turned up a natural peptide that mimics the drugs without the downsides.
Semaglutide improved memory, muscle function and blood sugar in older mice—and its benefits exceeded those of calorie restriction alone, prompting human trials.
Research finds the $100 coronary artery calcium scan rarely changes risk estimates for most adults, but can break statin ties in borderline cases.
Eurosurveillance links 48 child skin infections to a community party with three bouncy castles; 15 needed emergency care, four were hospitalized.
An infant and a child, both unvaccinated, died amid the worst U.S. measles outbreak in decades. Now federal and state officials are fighting over the data.
Insilico's one-year timelines, Novo Nordisk's Amazon pact, OpenAI's new model: AI is rewriting drug discovery—but funding and biology set the pace.
A case report in BMJ Case Reports describes a mid-childhood boy with a lace-like abdominal rash after resting a laptop on his body for hours a day.
Real-world study shows GLP-1 medications may cut asthma attacks by 40% and COPD exacerbations by 20%, expanding their potential reach beyond diabetes and weight loss.
The Department of Defense will tap the NIH’s NIAID budget for pandemic and CBRN threat research, a move critics denounce as a secretive diversion of health funds.
Swedish study of 15,000 patients finds semaglutide linked to 21% fewer psychiatric admissions; psychiatrists and lawsuits highlight mental health risk concerns.